ASCO 2015 | Results for the follow-up of the RESPONSE study

Jean-Jacques Kiladjian

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

Share this video  
Similar topics
Related videos
1:36
Sotatercept for MPN-associated myelofibrosis and anemia
Srdan Verstovsek
2:47
Analysis of JAK inhibitors and risk of secondary B-cell lymphomas in MPN patients
Naveen Pemmaraju
2:14
Key population-based registry studies in hematological oncology
Magnus Björkholm
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:30
LCL161 for primary myelofibrosis: a new therapy in the field
Naveen Pemmaraju
Myeloproliferative Neoplasms
Ruxolitinib
ASCO 2015
Presentation
2nd June 2015
More from Jean-Jacques Kiladjian
PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs
Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide
RUXOPEG: a promising novel combination for MPN-associated myelofibrosis
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals